The chapter
Engineering longer healthspan hinges on making tissue repair and systemic maintenance controllable, with the main bottlenecks being safe whole-body delivery, validated measures of aging and repair, and long-duration governance of powerful interventions. As of 2026, real-world impact still mostly comes from risk-factor control and disease prevention, while somatic gene therapy has reached regulated clinical use, including the first FDA-approved hemophilia gene therapy reported in 2023. CRISPR is advancing under tightening regulatory scrutiny amid complex IP. Practical priorities are scalable, tissue-selective delivery (often nanoparticles), robust tissue-expression baselines (e.g., GTEx), and selecting high-burden conditions as early healthspan ROI targets.
This record lists the chapter's canonical sources and its revisions as recorded on Comuvia's BookWriter and MediaManager systems. The chapter and its video are AI-authored and AI-produced; the sources ground the text, they do not endorse it.

Sources
The chapter's canonical source pack as recorded on BookWriter: milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers. Tier reflects citation strength, not Comuvia's endorsement.
| # | Type | Source | Tier | Found via |
|---|---|---|---|---|
| 1 | Paper | The CRISPR Patent Ruling and Implications for Medicine Paradise, Jordan · JAMA · 2023 · doi:10.1001/jama.2022.24986 | gold · highly cited | crossref |
| 2 | Paper | Daily briefing: CRISPR patent ruling won’t be the end of it Graham, Flora · Nature · 2022 · doi:10.1038/d41586-022-00721-3 | gold · highly cited | crossref |
| 3 | Paper | First FDA-Approved Gene Therapy for Hemophilia Larkin, Howard · JAMA · 2023 · doi:10.1001/jama.2022.23510 | gold · highly cited | crossref |
| 4 | Paper | Daily briefing: Safety review is big step towards the first FDA-approved CRISPR therapy Graham, Flora · Nature · 2023 · doi:10.1038/d41586-023-03409-4 | gold · highly cited | crossref |
| 5 | Paper | Engineering precision nanoparticles for drug delivery Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley et al. · 2020 · doi:10.1038/s41573-020-0090-8 | gold · highly cited | openalex 7,125 citations |
| 6 | Paper | Natural products in drug discovery: advances and opportunities Atanas G. Atanasov, Sergey B. Zotchev, Verena M. Dirsch et al. · 2021 · doi:10.1038/s41573-020-00114-z | gold · highly cited | openalex 4,811 citations |
| 7 | Paper | Gut microbiota in human metabolic health and disease Yong Fan, Oluf Pedersen · 2020 · doi:10.1038/s41579-020-0433-9 | gold · highly cited | openalex 4,421 citations |
| 8 | Paper | In silico analysis enabling informed design for genome editing in medicinal cannabis; gene families and variant characterisation Matchett-Oates, Lennon, Braich, Shivraj, Spangenberg, German et al. · 2019 · doi:10.26181/6153922fe919c | gold · highly cited | openalex 4,235 citations |
| 9 | Paper | A framework for advancing our understanding of cancer-associated fibroblasts Erik Sahai, Igor Astsaturov, Edna Cukierman et al. · 2020 · doi:10.1038/s41568-019-0238-1 | gold · highly cited | openalex 3,682 citations |
| 10 | Paper | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · 2017 · doi:10.1016/s0140-6736(17)32154-2 | gold · highly cited | openalex 13,473 citations |
| 11 | Paper | The Genotype-Tissue Expression (GTEx) project. John T. Lonsdale · 2013 · doi:10.1038/ng.2653 | gold · highly cited | openalex 9,907 citations |
| 12 | Paper | Nano based drug delivery systems: recent developments and future prospects Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto et al. · 2018 · doi:10.1186/s12951-018-0392-8 | gold · highly cited | openalex 6,407 citations |
Revisions
| When | Event | Detail |
|---|---|---|
| May 6, 2026 | Source pack version | version 4 · refresh coverage gap · 12 entries |
| May 6, 2026 | Source check | pass · coverage 100 % |
| Aug 29, 2026 | Upload (full) | uploaded · Ilv748CRkwo |
| Aug 29, 2026 | Upload (short_15s) | uploaded · giGSlsZQPPY |
| Sep 2, 2026 | Published on the channel | upload date as listed on the channel · SbB3ZhX7N_U |
About this record
Book: The Long Horizon: A Vision of Frontier Technology from 2026 to 2400 (BookWriter (Comuvia S2)). Channel: Comuvia Vision. Sources are the chapter's canonical source pack in BookWriter (milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers; tiers gold/strong by citation strength); revisions are the pack versions, the compliance checks and the campaign's uploads. The chapter text itself is AI-authored on BookWriter; the sources ground it, they do not endorse it.
anchor 86a27ab1-5cb8-4bf8-b5b2-f61bb6998566 · thread c5a53ff3-994d-4653-879c-9bf2fb0a0a29